Health

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

July 14, 2026 09:01 ET  | Source: Ernexa Therapeutics Inc. CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into…

12 hours ago

Dandy Unveils Polychromatic Shade to End the Trade-Off Between Dental Aesthetics and Affordability

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Dandy, the fully digital dental lab, today unveiled Polychromatic Shade™, a category-defining…

12 hours ago

Visory Health Wins a Digital Health Award for Second Consecutive Year

ESTERO, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Visory Health, one of the most used prescription discount cards, has won…

12 hours ago

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to…

1 day ago

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

July 13, 2026 11:08 ET  | Source: Zelluna ASA First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial…

1 day ago

Zealand Pharma – Transactions related to share buy-back program (week 28, 2026)

Company announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark,…

1 day ago

LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimers Disease Presented at the Alzheimers Association International Conference (AAIC) 2026

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients…

2 days ago

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept…

2 days ago

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

July 12, 2026 06:28 ET  | Source: Hemab Therapeutics, Inc. HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater…

2 days ago

SoliVana Wellness Lab Celebrates 3 years in Redwood City as the Bay Area’s First Dedicated Nervous System Recovery Center

Founded by two former enterprise executives, SoliVana combines 16 evidence-aligned therapies across 9 private rooms to address the stress and…

3 days ago